Most places are still just learning about it. If the percutaneous trial works, the interventional radiologists will be much keener to do this work because they do the case finding and can run their own scan rooms a little easier than day procedure rooms for endoscopists.
And Germany really is only the beginning of the government reimbursement rollout.
The company will have done the hard yards. COG will have lowered.
Any purchaser will have a much bigger and more more efficient regulatory, marketing, sales and education workforce. And the number of pancreatic cancer centres is limited.
If as a free standing company they can lower their costs to 10 mill pa they need to sell about 400 to breakeven. But I think that a prospective purchaser would need much less to be cash positive.
The US is still an expansion opportunity for Oncosil to sell to their prospective purchaser. If the TRIPP study is positive, a new company could confidently start a pivotal trial there. I have to say, though, that I think the company hasn't done enough to get research funding for Oncosil trials in the US. Getting a pivotal trial funded by NIH or someone else in the US would make a major difference to the company's rating. I guess I don;t know if they have been trying.
OSL Price at posting:
0.4¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)